Efficacy in lowering HbA1c Cardiovascular benefits Weight loss effects Patient preference Less Side effects
Monitoring HbA1c levels Evaluating weight loss Assessing cardiovascular outcomes Patient-reported outcomes
<0.5% 0.5-0.8% 0.8-1.2% >1.2%
HbA1c levels Renal function Comorbidities like HF Age Weight and BMI Side effects and tolerability
25/75% 40/60% 50/50% 75/25%
T2DM with ASCVD T2DM with CKD Heart failure patients (HFrEF or HFpEF) Patients with obesity
<10% 10-20% 21-30% >30%
≥60 mL/min/1.73 m2 45-59 mL/min/1.73 m2 30-44 mL/min/1.73 m2 <30 mL/min/1.73 m2
<2% 2-4% 5-7% >7%
Risk of genitourinary infections Cost of treatment Limited availability in certain regions Lack of long-term real-world evidence
<5% 5-10% 10-20% >20%
<50% 51-70% 71-90% >90%